Amgen (AMGN) Offering Possible 21.95% Return Over the Next 7 Calendar Days

Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $180.00 short put and a strike $175.00 long put offers a potential 21.95% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $180.00 by expiration. The full premium credit of $0.90 would be kept by the premium seller. The risk of $4.10 would be incurred if the stock dropped below the $175.00 long put strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.

The RSI indicator is at 56.77 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Amgen

Horizon Stock Pops On Beat And Raise As Another Drugmaker Reverses
Wed, 07 Aug 2019 20:31:32 +0000
Horizon Therapeutics stock popped Wednesday after its gout treatment, Krystexxa, drove a beat and raise in the second quarter. Adjusted Horizon earnings also came in better than expected.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Wed, 07 Aug 2019 10:45:10 +0000
Sector ETF report for PBE

Biotech ETFs in Focus on Impressive Q2 Earnings Results
Tue, 06 Aug 2019 20:22:08 +0000
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.

5 lsquo;Strong Buyrsquo; Dividend Stocks With High Upside
Tue, 06 Aug 2019 16:54:52 +0000
The markets are looking perilous right now, with rising trade tensions and Federal Reserve uncertainty sparking heavy selling. While there has been a flight out of stocks generally – Standard & Poor's 500-stock index is off almost 6% over the past five days – dividend stocks are gaining a little appeal.Investors were caught off guard after the Federal Reserve lowered its benchmark interest rate by a quarter-point. Some were expecting a half-point cut, and others were expecting Fed Chairman Jerome Powell to signal another quarter-point cut later in the year (he didn't). Then America's trade war with China flared up after President Donald Trump threatened a new round of tariffs, which the Chinese replied to by cutting off imports of U.S. agricultural products and momentarily letting its yuan currency slip above a key level.Dividend stocks can help smooth out returns during volatile periods like this. Morgan Stanley private wealth adviser Christopher Poch is a firm believer in dividend investing. He writes, "In over 33 years in the wealth management industry, I have seen what works for the long-term, tax paying investor. The importance of dividends and the contribution to overall total return, for new and experienced investors alike, should not be overlooked.""Not only do dividend stocks as a group have less volatility year- to- year, they outperform nondividend paying stocks over time as well," Poch writes. "Over the last 90+ years, dividends have accounted for more than 40% of the total return equation."Here are five dividend stocks that TipRanks has identified as earning a "Strong Buy" rating by Wall Street's analyst community. Each of these stocks boasts relatively high yields between 3% and 5% – well more than the broader market's current 1.9% – and are projected to gain between 17% and 65% over the next 12 months. SEE ALSO: 57 Dividend Stocks You Can Count On in 2019

Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
Tue, 06 Aug 2019 14:19:02 +0000
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.